WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2023)
Top diagnostic & research stocks in 2023 ranked by overall Zen Score. See the best diagnostic & research stocks to buy now, according to analyst forecasts for the diagnostics & research industry.

Industry: Diagnostics & Research
Ticker
Company
Exchange
Industry
Zen Score
Market Cap
Price
1d %
EBITDA
P/E
D/E
ENZ
ENZO BIOCHEM INC
NYSE
Diagnostics & Research
$63.11M$1.250.00%$24.09M3.05x0.55
FONR
FONAR CORP
NASDAQ
Diagnostics & Research
$130.04M$19.03-0.63%$24.26M11.46x0.29
QGEN
QIAGEN NV
NYSE
Diagnostics & Research
$9.39B$41.16-0.17%$840.36M19.42x0.60
CRL
CHARLES RIVER LABORATORIES INTERNATIONAL INC
NYSE
Diagnostics & Research
$10.11B$197.08-0.01%$1.06B21.19x1.29
IDXX
IDEXX LABORATORIES INC
NASDAQ
Diagnostics & Research
$38.69B$465.82-0.20%$1.19B47.01x1.38
RVTY
REVVITY INC
NYSE
Diagnostics & Research
$10.97B$88.90-0.57%$1.31B15.12x0.74
STRR
STAR EQUITY HOLDINGS INC
NASDAQ
Diagnostics & Research
$17.57M$1.115.71%$29.21M0.59x0.18
MEDP
MEDPACE HOLDINGS INC
NASDAQ
Diagnostics & Research
$8.31B$270.72-0.46%$366.17M30.66x2.16
ICLR
ICON PLC
NASDAQ
Diagnostics & Research
$21.95B$266.94-0.02%$1.48B42.57x0.90
A
AGILENT TECHNOLOGIES INC
NYSE
Diagnostics & Research
$37.39B$127.800.16%$1.75B33.37x0.92
EXAS
EXACT SCIENCES CORP
NASDAQ
Diagnostics & Research
$11.57B$64.00-1.63%-$37.28M-40.25x1.06
DGX
QUEST DIAGNOSTICS INC
NYSE
Diagnostics & Research
$15.43B$137.231.45%$1.56B20.18x1.09
CSTL
CASTLE BIOSCIENCES INC
NASDAQ
Diagnostics & Research
$537.94M$19.990.65%-$63.43M-7.01x0.13
TWST
TWIST BIOSCIENCE CORP
NASDAQ
Diagnostics & Research
$1.39B$24.05-1.88%-$171.58M-6.68x0.25
LH
LABORATORY CORP OF AMERICA HOLDINGS
NYSE
Diagnostics & Research
$18.42B$216.911.32%$1.76B28.47x1.14
OLK
OLINK HOLDING AB (PUBL)
NASDAQ
Diagnostics & Research
$3.21B$25.85-0.15%-$4.48M-172.33x0.17
DHR
DANAHER CORP
NYSE
Diagnostics & Research
$165.01B$223.310.36%$9.29B27.81x0.67
TMO
THERMO FISHER SCIENTIFIC INC
NYSE
Diagnostics & Research
$191.55B$495.760.58%$10.93B32.32x1.14
DMTK
DERMTECH INC
NASDAQ
Diagnostics & Research
$55.13M$1.61-3.59%-$104.04M-0.46x0.89
DRIO
DARIOHEALTH CORP
NASDAQ
Diagnostics & Research
$32.93M$1.21-6.20%-$52.84M-0.60x0.57
CDNA
CAREDX INC
NASDAQ
Diagnostics & Research
$525.30M$9.71-0.51%-$81.67M-5.78x0.27
MTD
METTLER TOLEDO INTERNATIONAL INC
NYSE
Diagnostics & Research
$23.68B$1,091.93-0.05%$1.26B27.68x-32.06
WAT
WATERS CORP
NYSE
Diagnostics & Research
$16.59B$280.610.31%$1.01B25.44x3.97
APDN
APPLIED DNA SCIENCES INC
NASDAQ
Diagnostics & Research
$12.02M$0.88-2.22%-$5.67M-1.83x1.19
SERA
SERA PROGNOSTICS INC
NASDAQ
Diagnostics & Research
$60.79M$1.942.65%-$36.59M-1.58x0.19
BNR
BURNING ROCK BIOTECH LTD
NASDAQ
Diagnostics & Research
$84.93M$0.83-7.26%N/A-0.85x0.35
RDNT
RADNET INC
NASDAQ
Diagnostics & Research
$2.26B$33.231.00%$268.49M1,661.50x3.06
FLGT
FULGENT GENETICS INC
NASDAQ
Diagnostics & Research
$817.28M$27.58-0.18%-$24.97M-13.07x0.08
GH
GUARDANT HEALTH INC
NASDAQ
Diagnostics & Research
$2.97B$25.170.20%-$378.56M-6.18x6.87
NTRA
NATERA INC
NASDAQ
Diagnostics & Research
$6.72B$55.95-1.22%-$450.69M-12.38x0.84
LAB
STANDARD BIOTOOLS INC
NASDAQ
Diagnostics & Research
$204.84M$2.582.79%-$66.69M-2.69x-1.21
NEOG
NEOGEN CORP
NASDAQ
Diagnostics & Research
$3.67B$16.970.12%$158.76M-169.70x0.45
BGLC
BIONEXUS GENE LAB CORP
NASDAQ
Diagnostics & Research
$16.78M$0.95-12.84%-$2.87M-11.31x0.18
NOTV
INOTIV INC
NASDAQ
Diagnostics & Research
$63.68M$2.47-3.14%-$271.83M-0.18x2.10
NEO
NEOGENOMICS INC
NASDAQ
Diagnostics & Research
$2.32B$18.17-1.73%-$33.48M-23.60x0.77
ACRS
ACLARIS THERAPEUTICS INC
NASDAQ
Diagnostics & Research
$61.98M$0.88-0.34%-$113.80M-0.53x0.40
PRPO
PRECIPIO INC
NASDAQ
Diagnostics & Research
$9.69M$6.83-2.49%-$7.53M-0.92x0.47
XWEL
XWELL INC
NASDAQ
Diagnostics & Research
$9.95M$2.380.85%-$30.04M-0.29x0.89
GTH
GENETRON HOLDINGS LTD
NASDAQ
Diagnostics & Research
$112.71M$3.680.14%-$101.00M-0.97x0.78
AWH
ASPIRA WOMEN's HEALTH INC
NASDAQ
Diagnostics & Research
$32.87M$3.18-0.93%-$20.74M-1.28x-14.14
PSNL
PERSONALIS INC
NASDAQ
Diagnostics & Research
$75.02M$1.532.00%-$97.69M-0.64x0.50
PRPH
PROPHASE LABS INC
NASDAQ
Diagnostics & Research
$91.49M$5.078.57%-$9.64M-8.05x0.63
ME
23ANDME HOLDING CO
NASDAQ
Diagnostics & Research
$412.51M$0.86-3.91%-$303.26M-1.18x0.28
STIM
NEURONETICS INC
NASDAQ
Diagnostics & Research
$52.66M$1.8221.33%-$26.20M-1.54x1.45
CHEK
CHECK-CAP LTD
NASDAQ
Diagnostics & Research
$17.02M$2.91-0.38%-$19.08M-0.96x0.06
GENE
GENETIC TECHNOLOGIES LTD
NASDAQ
Diagnostics & Research
$16.85M$0.731.39%-$7.71M-15.53x0.33
NVTA
INVITAE CORP
NYSE
Diagnostics & Research
$145.54M$0.51-1.74%-$1.27B-0.10x-1.49
BIAF
BIOAFFINITY TECHNOLOGIES INC
NASDAQ
Diagnostics & Research
$15.77M$1.6622.96%-$7.04M-3.95x0.46
OPK
OPKO HEALTH INC
NASDAQ
Diagnostics & Research
$1.13B$1.46-4.58%-$95.00M-5.21x0.42
ILMN
ILLUMINA INC
NASDAQ
Diagnostics & Research
$16.19B$101.950.37%-$621.00M-14.36x0.72
NDRA
ENDRA LIFE SCIENCES INC
NASDAQ
Diagnostics & Research
$8.39M$0.993.12%-$11.61M-0.36x0.46
ISPC
ISPECIMEN INC
NASDAQ
Diagnostics & Research
$5.08M$0.560.00%-$8.17M-0.50x0.28
XGN
EXAGEN INC
NASDAQ
Diagnostics & Research
$31.36M$1.8421.05%-$27.23M-0.99x1.22
MYGN
MYRIAD GENETICS INC
NASDAQ
Diagnostics & Research
$1.57B$19.09-0.78%-$206.90M-5.68x0.68
IQV
IQVIA HOLDINGS INC
NYSE
Diagnostics & Research
$39.07B$214.100.14%$3.15B35.33x3.48
SHC
SOTERA HEALTH CO
NASDAQ
Diagnostics & Research
$3.86B$13.650.44%-$51.99M-12.41x7.05
PMD
PSYCHEMEDICS CORP
NASDAQ
Diagnostics & Research
$14.85M$2.565.35%-$67.00k-3.76x0.90
PRE
PRENETICS GLOBAL LTD
NASDAQ
Diagnostics & Research
$49.32M$4.20-0.71%N/A-1.04x0.21
BDSX
BIODESIX INC
NASDAQ
Diagnostics & Research
$134.81M$1.490.00%-$47.74M-1.69x-61.02
OCX
ONCOCYTE CORP
NASDAQ
Diagnostics & Research
$31.39M$3.800.00%-$54.87M-0.40x1.04
LMDX
LUMIRADX LTD
NASDAQ
Diagnostics & Research
$54.85M$0.1747.01%-$226.37M-0.16x-2.60
VNRX
VOLITIONRX LTD
NYSEMKT
Diagnostics & Research
$59.64M$0.76-1.56%-$32.28M-1.43x-10.23
CNTG
CENTOGENE NV
NASDAQ
Diagnostics & Research
$35.10M$1.272.33%-$44.39M-0.81x-5.72
MDXH
MDXHEALTH SA
NASDAQ
Diagnostics & Research
$8.73M$3.23-0.31%N/AN/A6.61
TTOO
T2 BIOSYSTEMS INC
NASDAQ
Diagnostics & Research
$14.34M$3.54-2.75%-$41.78M-0.02x-3.25
TRIB
TRINITY BIOTECH PLC
NASDAQ
Diagnostics & Research
$18.18M$0.483.02%N/AN/A-7.33
MYNZ
MAINZ BIOMED NV
NASDAQ
Diagnostics & Research
$17.82M$1.145.56%N/AN/A4.19

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Dec 2023?

According to Zen Score, the 3 best diagnostic & research stocks to buy right now are:

1. Enzo Biochem (NYSE:ENZ)


Enzo Biochem (NYSE:ENZ) is the top diagnostic & research stock with a Zen Score of 51, which is 24 points higher than the diagnostic & research industry average of 27. It passed 16 out of 33 due diligence checks and has strong fundamentals. Enzo Biochem has seen its stock lose -37.19% over the past year, underperforming other diagnostic & research stocks by -20 percentage points.

2. Qiagen Nv (NYSE:QGEN)


Qiagen Nv (NYSE:QGEN) is the second best diagnostic & research stock with a Zen Score of 47, which is 20 points higher than the diagnostic & research industry average of 27. It passed 15 out of 33 due diligence checks and has strong fundamentals. Qiagen Nv has seen its stock lose -16.92% over the past year.

Qiagen Nv has an average 1 year price target of $50.50, an upside of 22.69% from Qiagen Nv's current stock price of $41.16.

Qiagen Nv stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Qiagen Nv, 50% have issued a Strong Buy rating, 25% have issued a Buy, 25% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Fonar (NASDAQ:FONR)


Fonar (NASDAQ:FONR) is the third best diagnostic & research stock with a Zen Score of 47, which is 20 points higher than the diagnostic & research industry average of 27. It passed 14 out of 33 due diligence checks and has strong fundamentals. Fonar has seen its stock return 1.12% over the past year, overperforming other diagnostic & research stocks by 18 percentage points.

What are the diagnostic & research stocks with highest dividends?

Out of 6 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Quest Diagnostics (NYSE:DGX)


Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 2.03%, which is 1 percentage points higher than the diagnostic & research industry average of 1.51%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 41% indicates that its dividend yield is sustainable for the long-term.

2. Laboratory Of America Holdings (NYSE:LH)


Laboratory Of America Holdings (NYSE:LH) has an annual dividend yield of 1.33%, which is the same as the diagnostic & research industry average of 1.51%. Laboratory Of America Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Laboratory Of America Holdings's dividend has not shown consistent growth over the last 10 years.

Laboratory Of America Holdings's dividend payout ratio of 37.8% indicates that its dividend yield is sustainable for the long-term.

3. Agilent Technologies (NYSE:A)


Agilent Technologies (NYSE:A) has an annual dividend yield of 0.7%, which is -1 percentage points lower than the diagnostic & research industry average of 1.51%. Agilent Technologies's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Agilent Technologies's dividend has shown consistent growth over the last 10 years.

Agilent Technologies's dividend payout ratio of 23.1% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks up?

Diagnostic & research stocks were up 0.12% in the last day, and down -0.14% over the last week.

We couldn't find a catalyst for why diagnostic & research stocks are up.

What are the most undervalued diagnostic & research stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued diagnostic & research stocks right now are:

1. Enzo Biochem (NYSE:ENZ)


Enzo Biochem (NYSE:ENZ) is the most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Enzo Biochem has a valuation score of 71, which is 50 points higher than the diagnostic & research industry average of 21. It passed 5 out of 7 valuation due diligence checks.

Enzo Biochem's stock has dropped -37.19% in the past year. It has underperformed other stocks in the diagnostic & research industry by -20 percentage points.

2. Star Equity Holdings (NASDAQ:STRR)


Star Equity Holdings (NASDAQ:STRR) is the second most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Star Equity Holdings has a valuation score of 71, which is 50 points higher than the diagnostic & research industry average of 21. It passed 5 out of 7 valuation due diligence checks.

Star Equity Holdings's stock has gained 14.43% in the past year. It has overperformed other stocks in the diagnostic & research industry by 31 percentage points.

3. Fonar (NASDAQ:FONR)


Fonar (NASDAQ:FONR) is the third most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Fonar has a valuation score of 71, which is 50 points higher than the diagnostic & research industry average of 21. It passed 5 out of 7 valuation due diligence checks.

Fonar's stock has gained 1.12% in the past year. It has overperformed other stocks in the diagnostic & research industry by 18 percentage points.

Are diagnostic & research stocks a good buy now?

54.9% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 16.24% over the next year.

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 30.73x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.